- Home
- HITI vs INZY Comparison
HITI vs INZY Comparison
Compare HITI & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HITI
- INZY
- Stock Information
- Founded
- HITI 2009
- INZY 2015
- Country
- HITI Canada
- INZY United States
- Employees
- HITI N/A
- INZY N/A
- Industry
- HITI
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- HITI
- INZY Health Care
- Exchange
- HITI Nasdaq
- INZY Nasdaq
- Market Cap
- HITI 249.3M
- INZY 188.2M
- IPO Year
- HITI N/A
- INZY 2020
- Fundamental
- Price
- HITI $3.09
- INZY $1.36
- Analyst Decision
- HITI Strong Buy
- INZY Strong Buy
- Analyst Count
- HITI 1
- INZY 8
- Target Price
- HITI $4.50
- INZY $17.75
- AVG Volume (30 Days)
- HITI 641.5K
- INZY 784.0K
- Earning Date
- HITI 03-14-2025
- INZY 03-11-2025
- Dividend Yield
- HITI N/A
- INZY N/A
- EPS Growth
- HITI N/A
- INZY N/A
- EPS
- HITI N/A
- INZY N/A
- Revenue
- HITI $370,017,302.00
- INZY N/A
- Revenue This Year
- HITI $7.52
- INZY N/A
- Revenue Next Year
- HITI $14.03
- INZY N/A
- P/E Ratio
- HITI N/A
- INZY N/A
- Revenue Growth
- HITI 9.02
- INZY N/A
- 52 Week Low
- HITI $1.57
- INZY $1.32
- 52 Week High
- HITI $3.62
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- HITI 48.76
- INZY 20.27
- Support Level
- HITI $3.01
- INZY $1.32
- Resistance Level
- HITI $3.23
- INZY $3.18
- Average True Range (ATR)
- HITI 0.15
- INZY 0.27
- MACD
- HITI -0.02
- INZY -0.15
- Stochastic Oscillator
- HITI 32.14
- INZY 2.15
About HITI High Tide Inc.
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically-integrated company in the Canadian cannabis market with portfolio subsidiaries including RGR Canada Inc., Famous Brandz Inc., Kush West Distribution Inc., Smoker's Corner Ltd., Grasscity.com, Canna Cabana Inc., and KushBar Inc. The firm has established two main segments, retail and wholesale. It generates substantial revenue from retail stores' e-commerce platforms. Geographically it serves Canada, the USA, and other international markets and earns key revenue from domestic sales.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.